Real-World Overall Survival With Abiraterone Acetate and Enzalutamide in Patients With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer From the Flatiron Electronic Health Records Database

Background

Patients with chemotherapy- and androgen receptor pathway inhibitor (ARPI)-naïve metastatic castration-resistant prostate cancer (mCRPC) have generally shown worse overall survival (OS) with abiraterone versus enzalutamide in claims database studies. Given limitations of claims data, analysis using detailed electronic health records (EHRs) is needed to confirm this finding.